Difference between revisions of "Breast cancer, BRCA-mutated"
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable" style="width: 100%" to "{| class="wikitable sortable" style="width: 100%") |
m |
||
Line 11: | Line 11: | ||
*'''2011:''' [http://annonc.oxfordjournals.org/content/22/suppl_6/vi31.full.pdf+html BRCA in breast cancer: ESMO Clinical Practice Guidelines] [https://pubmed.ncbi.nlm.nih.gov/21908500 PubMed] | *'''2011:''' [http://annonc.oxfordjournals.org/content/22/suppl_6/vi31.full.pdf+html BRCA in breast cancer: ESMO Clinical Practice Guidelines] [https://pubmed.ncbi.nlm.nih.gov/21908500 PubMed] | ||
− | =Advanced or metastatic disease, | + | =Advanced or metastatic disease, subsequent lines of therapy= |
==Capecitabine monotherapy {{#subobject:842c42|Regimen=1}}== | ==Capecitabine monotherapy {{#subobject:842c42|Regimen=1}}== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
Line 32: | Line 32: | ||
|- | |- | ||
|} | |} | ||
− | + | ====Biomarker eligibility criteria==== | |
+ | *Confirmed deleterious or suspected deleterious germline BRCA mutation | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Capecitabine (Xeloda)]] 1250 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | *[[Capecitabine (Xeloda)]] 1250 mg/m<sup>2</sup> PO twice per day on days 1 to 14 | ||
Line 40: | Line 41: | ||
# '''OlympiAD:''' Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. [https://www.nejm.org/doi/full/10.1056/NEJMoa1706450 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/28578601 PubMed] | # '''OlympiAD:''' Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. [https://www.nejm.org/doi/full/10.1056/NEJMoa1706450 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/28578601 PubMed] | ||
## '''Update:''' Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Apr 1;30(4):558-566. [https://doi.org/10.1093/annonc/mdz012 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503629/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30689707 PubMed] | ## '''Update:''' Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Apr 1;30(4):558-566. [https://doi.org/10.1093/annonc/mdz012 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503629/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30689707 PubMed] | ||
+ | |||
+ | ==Carboplatin monotherapy {{#subobject:16h4a8|Regimen=1}}== | ||
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#top|back to top]] | ||
+ | |} | ||
+ | ===Regimen {{#subobject:ujsx06|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | !style="width: 20%"|Study | ||
+ | !style="width: 20%"|Years of enrollment | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 20%"|Comparator | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372067/ Tutt et al. 2018 (TNT)] | ||
+ | |2008-2014 | ||
+ | |style="background-color:#1a9851"|Phase III (E-switch-ic) | ||
+ | |[[#Docetaxel_monotherapy|Docetaxel]] | ||
+ | | style="background-color:#1a9850" |Superior ORR (*) | ||
+ | |- | ||
+ | |} | ||
+ | ''Note: the rerported efficacy is based on subgroup analysis.'' | ||
+ | ====Chemotherapy==== | ||
+ | *[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1 | ||
+ | |||
+ | '''21-day cycle for 6 to 8 cycles''' | ||
+ | |||
+ | ===References=== | ||
+ | # '''TNT:''' Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder SE, Bliss JM. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018 May;24(5):628-637. Epub 2018 Apr 30. [https://www.nature.com/articles/s41591-018-0009-7 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372067/ link to PMC article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/29713086 PubMed] | ||
+ | |||
+ | ==Carboplatin & Paclitaxel {{#subobject:842252|Regimen=1}}== | ||
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#top|back to top]] | ||
+ | |} | ||
+ | ===Regimen {{#subobject:f16cn0|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | !style="width: 20%"|Study | ||
+ | !style="width: 20%"|Years of enrollment | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 20%"|Comparator | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1016/s1470-2045(20)30447-2 Diéras et al. 2020 (BROCADE3)] | ||
+ | |2014-2018 | ||
+ | | style="background-color:#1a9851" |Phase III (C) | ||
+ | |CP & Veliparib | ||
+ | | style="background-color:#d73027" |Inferior PFS | ||
+ | |- | ||
+ | |} | ||
+ | ====Biomarker eligibility criteria==== | ||
+ | *Confirmed deleterious germline BRCA1 or BRCA2 mutation | ||
+ | ====Chemotherapy==== | ||
+ | *[[Carboplatin (Paraplatin)]] AUC 6 IV once on day 1 | ||
+ | *[[Paclitaxel (Taxol)]] 80 mg/m<sup>2</sup> IV once per day on days 1, 8, 15 | ||
+ | |||
+ | '''21-day cycles''' | ||
+ | |||
+ | ===References=== | ||
+ | #'''BROCADE3:''' Diéras V, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL, Bondarenko I, Campone M, Jakobsen EH, Jalving M, Oprean C, Palácová M, Park YH, Shparyk Y, Yañez E, Khandelwal N, Kundu MG, Dudley M, Ratajczak CK, Maag D, Arun BK. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 Oct;21(10):1269-1282. Epub 2020 Aug 27. [https://doi.org/10.1016/s1470-2045(20)30447-2 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/32861273 PubMed] NCT02163694 | ||
+ | |||
+ | ==Docetaxel monotherapy {{#subobject:3e34a8|Regimen=1}}== | ||
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#top|back to top]] | ||
+ | |} | ||
+ | ===Regimen {{#subobject:71bf06|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | !style="width: 20%"|Study | ||
+ | !style="width: 20%"|Years of enrollment | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | !style="width: 20%"|Comparator | ||
+ | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372067/ Tutt et al. 2018 (TNT)] | ||
+ | |2008-2014 | ||
+ | |style="background-color:#1a9851"|Phase III (C) | ||
+ | |[[#Carboplatin_monotherapy|Carboplatin]] | ||
+ | | style="background-color:#d73027" |Inferior ORR (*) | ||
+ | |- | ||
+ | |} | ||
+ | ''Note: the rerported efficacy is based on subgroup analysis.'' | ||
+ | ====Chemotherapy==== | ||
+ | *[[Docetaxel (Taxotere)]] 100 mg/m<sup>2</sup> IV once on day 1 | ||
+ | |||
+ | '''21-day cycle for 6 to 8 cycles''' | ||
+ | |||
+ | ===References=== | ||
+ | # '''TNT:''' Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder SE, Bliss JM. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018 May;24(5):628-637. Epub 2018 Apr 30. [https://www.nature.com/articles/s41591-018-0009-7 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372067/ link to PMC article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/29713086 PubMed] | ||
==Eribulin monotherapy {{#subobject:ef2415|Regimen=1}}== | ==Eribulin monotherapy {{#subobject:ef2415|Regimen=1}}== | ||
Line 61: | Line 151: | ||
|- | |- | ||
|} | |} | ||
− | + | ====Biomarker eligibility criteria==== | |
+ | *Confirmed deleterious or suspected deleterious germline BRCA mutation | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Eribulin (Halaven)]] 1.4 mg/m<sup>2</sup> IV over 2 to 5 minutes once per day on days 1 & 8 | *[[Eribulin (Halaven)]] 1.4 mg/m<sup>2</sup> IV over 2 to 5 minutes once per day on days 1 & 8 | ||
Line 70: | Line 161: | ||
# '''OlympiAD:''' Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. [https://www.nejm.org/doi/full/10.1056/NEJMoa1706450 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/28578601 PubMed] | # '''OlympiAD:''' Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. [https://www.nejm.org/doi/full/10.1056/NEJMoa1706450 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/28578601 PubMed] | ||
## '''Update:''' Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Apr 1;30(4):558-566. [https://doi.org/10.1093/annonc/mdz012 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503629/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30689707 PubMed] | ## '''Update:''' Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Apr 1;30(4):558-566. [https://doi.org/10.1093/annonc/mdz012 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503629/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30689707 PubMed] | ||
+ | # '''EMBRACA:''' Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018 Aug 23;379(8):753-763. Epub 2018 Aug 15. [https://www.nejm.org/doi/full/10.1056/NEJMoa1802905 link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/30110579 PubMed] | ||
==Olaparib monotherapy {{#subobject:a019cd|Regimen=1}}== | ==Olaparib monotherapy {{#subobject:a019cd|Regimen=1}}== | ||
Line 77: | Line 169: | ||
|} | |} | ||
===Regimen variant #1, 100 mg twice per day {{#subobject:31ed8c|Variant=1}}=== | ===Regimen variant #1, 100 mg twice per day {{#subobject:31ed8c|Variant=1}}=== | ||
− | {| class="wikitable" style="width: | + | {| class="wikitable sortable" style="width: 75%; text-align:center;" |
− | !style="width: | + | !style="width: 33%"|Study |
− | !style="width: | + | !style="width: 33%"|Years of enrollment |
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
− | |[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60892-6/fulltext Tutt et al. 2010] | + | |[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60892-6/fulltext Tutt et al. 2010 (KU36-44)] |
+ | |2007-2008 | ||
|style="background-color:#91cf61"|Phase II | |style="background-color:#91cf61"|Phase II | ||
|- | |- | ||
Line 112: | Line 206: | ||
===Regimen variant #3, 400 mg twice per day {{#subobject:31cf8c|Variant=1}}=== | ===Regimen variant #3, 400 mg twice per day {{#subobject:31cf8c|Variant=1}}=== | ||
− | {| class="wikitable" style="width: | + | {| class="wikitable sortable" style="width: 75%; text-align:center;" |
− | !style="width: | + | !style="width: 33%"|Study |
− | !style="width: | + | !style="width: 33%"|Years of enrollment |
+ | !style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
|- | |- | ||
− | |[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60892-6/fulltext Tutt et al. 2010] | + | |[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60892-6/fulltext Tutt et al. 2010 (KU36-44)] |
+ | |2007-2008 | ||
|style="background-color:#91cf61"|Phase II | |style="background-color:#91cf61"|Phase II | ||
|- | |- | ||
− | |[http://jco.ascopubs.org/content/33/3/244.long Kaufman et al. 2014 ( | + | |[http://jco.ascopubs.org/content/33/3/244.long Kaufman et al. 2014 (D0810C00042)] |
+ | |2010-NR | ||
|style="background-color:#91cf61"|Phase II | |style="background-color:#91cf61"|Phase II | ||
|- | |- | ||
|} | |} | ||
− | ''Patients in | + | ''Patients in D0810C00042 had germline BRCA1/2 mutations and had progressed after at least three lines of treatment for metastatic disease.'' |
====Targeted therapy==== | ====Targeted therapy==== | ||
*[[Olaparib (Lynparza)]] 400 mg PO twice per day | *[[Olaparib (Lynparza)]] 400 mg PO twice per day | ||
Line 130: | Line 227: | ||
===References=== | ===References=== | ||
− | # Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010 Jul 24;376(9737):235-44. Epub 2010 Jul 6. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60892-6/fulltext link to original article] [https://pubmed.ncbi.nlm.nih.gov/20609467 PubMed] | + | # '''KU36-44:''' Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010 Jul 24;376(9737):235-44. Epub 2010 Jul 6. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60892-6/fulltext link to original article] [https://pubmed.ncbi.nlm.nih.gov/20609467 PubMed] NCT00494234 |
<!-- Presented at the 49th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 4, 2013. --> | <!-- Presented at the 49th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 4, 2013. --> | ||
− | # ''' | + | # '''D0810C00042:''' Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015 Jan 20;33(3):244-50. Epub 2014 Nov 3. [http://jco.ascopubs.org/content/33/3/244.long link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/25366685 PubMed] NCT01078662 |
# '''OlympiAD:''' Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. [https://www.nejm.org/doi/full/10.1056/NEJMoa1706450 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/28578601 PubMed] | # '''OlympiAD:''' Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. [https://www.nejm.org/doi/full/10.1056/NEJMoa1706450 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/28578601 PubMed] | ||
## '''Update:''' Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Apr 1;30(4):558-566. [https://doi.org/10.1093/annonc/mdz012 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503629/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30689707 PubMed] | ## '''Update:''' Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Apr 1;30(4):558-566. [https://doi.org/10.1093/annonc/mdz012 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503629/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30689707 PubMed] | ||
Line 156: | Line 253: | ||
|2013-2017 | |2013-2017 | ||
| style="background-color:#1a9851" |Phase III (E-RT-switch-ooc) | | style="background-color:#1a9851" |Phase III (E-RT-switch-ooc) | ||
− | |Physician's choice of:<br> 1. [[#Capecitabine_monotherapy|Capecitabine]]<br> 2. Eribulin<br> 3. Gemcitabine<br> 4. Vinorelbine | + | |Physician's choice of:<br> 1. [[#Capecitabine_monotherapy|Capecitabine]]<br> 2. [[#Eribulin_monotherapy|Eribulin]]<br> 3. Gemcitabine<br> 4. [[#Vinorelbine_monotherapy|Vinorelbine]] |
| style="background-color:#1a9850" |Superior PFS | | style="background-color:#1a9850" |Superior PFS | ||
|- | |- | ||
Line 196: | Line 293: | ||
# '''OlympiAD:''' Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. [https://www.nejm.org/doi/full/10.1056/NEJMoa1706450 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/28578601 PubMed] | # '''OlympiAD:''' Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. [https://www.nejm.org/doi/full/10.1056/NEJMoa1706450 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/28578601 PubMed] | ||
## '''Update:''' Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Apr 1;30(4):558-566. [https://doi.org/10.1093/annonc/mdz012 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503629/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30689707 PubMed] | ## '''Update:''' Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Apr 1;30(4):558-566. [https://doi.org/10.1093/annonc/mdz012 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503629/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/30689707 PubMed] | ||
+ | # '''EMBRACA:''' Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018 Aug 23;379(8):753-763. Epub 2018 Aug 15. [https://www.nejm.org/doi/full/10.1056/NEJMoa1802905 link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/30110579 PubMed] | ||
=Additional resources= | =Additional resources= |
Revision as of 17:52, 11 October 2020
10 regimens on this page
13 variants on this page
|
Note: this page has regimens which are specific to breast cancer that is BRCA-mutated. Please see the main breast cancer page for other chemotherapy regimens.
Guidelines
ESMO
Advanced or metastatic disease, subsequent lines of therapy
Capecitabine monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Robson et al. 2017 (OlympiAD) | 2014-2015 | Phase III (C) | Olaparib | Inferior PFS |
Biomarker eligibility criteria
- Confirmed deleterious or suspected deleterious germline BRCA mutation
Chemotherapy
- Capecitabine (Xeloda) 1250 mg/m2 PO twice per day on days 1 to 14
21-day cycles
References
- OlympiAD: Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. link to original article contains verified protocol PubMed
- Update: Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Apr 1;30(4):558-566. link to original article link to PMC article PubMed
Carboplatin monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Tutt et al. 2018 (TNT) | 2008-2014 | Phase III (E-switch-ic) | Docetaxel | Superior ORR (*) |
Note: the rerported efficacy is based on subgroup analysis.
Chemotherapy
- Carboplatin (Paraplatin) AUC 6 IV once on day 1
21-day cycle for 6 to 8 cycles
References
- TNT: Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder SE, Bliss JM. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018 May;24(5):628-637. Epub 2018 Apr 30. link to original article link to PMC article contains verified protocol PubMed
Carboplatin & Paclitaxel
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Diéras et al. 2020 (BROCADE3) | 2014-2018 | Phase III (C) | CP & Veliparib | Inferior PFS |
Biomarker eligibility criteria
- Confirmed deleterious germline BRCA1 or BRCA2 mutation
Chemotherapy
- Carboplatin (Paraplatin) AUC 6 IV once on day 1
- Paclitaxel (Taxol) 80 mg/m2 IV once per day on days 1, 8, 15
21-day cycles
References
- BROCADE3: Diéras V, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, Puhalla SL, Bondarenko I, Campone M, Jakobsen EH, Jalving M, Oprean C, Palácová M, Park YH, Shparyk Y, Yañez E, Khandelwal N, Kundu MG, Dudley M, Ratajczak CK, Maag D, Arun BK. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 Oct;21(10):1269-1282. Epub 2020 Aug 27. link to original article contains verified protocol PubMed NCT02163694
Docetaxel monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Tutt et al. 2018 (TNT) | 2008-2014 | Phase III (C) | Carboplatin | Inferior ORR (*) |
Note: the rerported efficacy is based on subgroup analysis.
Chemotherapy
- Docetaxel (Taxotere) 100 mg/m2 IV once on day 1
21-day cycle for 6 to 8 cycles
References
- TNT: Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder SE, Bliss JM. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med. 2018 May;24(5):628-637. Epub 2018 Apr 30. link to original article link to PMC article contains verified protocol PubMed
Eribulin monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Robson et al. 2017 (OlympiAD) | 2014-2015 | Phase III (C) | Olaparib | Inferior PFS |
Biomarker eligibility criteria
- Confirmed deleterious or suspected deleterious germline BRCA mutation
Targeted therapy
- Eribulin (Halaven) 1.4 mg/m2 IV over 2 to 5 minutes once per day on days 1 & 8
21-day cycles
References
- OlympiAD: Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. link to original article contains verified protocol PubMed
- Update: Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Apr 1;30(4):558-566. link to original article link to PMC article PubMed
- EMBRACA: Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018 Aug 23;379(8):753-763. Epub 2018 Aug 15. link to original article contains protocol PubMed
Olaparib monotherapy
back to top |
Regimen variant #1, 100 mg twice per day
Study | Years of enrollment | Evidence |
---|---|---|
Tutt et al. 2010 (KU36-44) | 2007-2008 | Phase II |
Targeted therapy
- Olaparib (Lynparza) 100 mg PO twice per day
Continued indefinitely
Regimen variant #2, 300 mg twice per day
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Robson et al. 2017 (OlympiAD) | 2014-2015 | Phase III (E-RT-switch-ooc) | 1. Capecitabine 2. Eribulin 3. Vinorelbine |
Superior PFS |
Patients had confirmed deleterious or suspected deleterious germline BRCA mutation. This is the FDA-approved dose.
Targeted therapy
- Olaparib (Lynparza) 300 mg PO twice per day
Continued indefinitely
Regimen variant #3, 400 mg twice per day
Study | Years of enrollment | Evidence |
---|---|---|
Tutt et al. 2010 (KU36-44) | 2007-2008 | Phase II |
Kaufman et al. 2014 (D0810C00042) | 2010-NR | Phase II |
Patients in D0810C00042 had germline BRCA1/2 mutations and had progressed after at least three lines of treatment for metastatic disease.
Targeted therapy
- Olaparib (Lynparza) 400 mg PO twice per day
Continued indefinitely
References
- KU36-44: Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010 Jul 24;376(9737):235-44. Epub 2010 Jul 6. link to original article PubMed NCT00494234
- D0810C00042: Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015 Jan 20;33(3):244-50. Epub 2014 Nov 3. link to original article contains verified protocol PubMed NCT01078662
- OlympiAD: Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. link to original article contains verified protocol PubMed
- Update: Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Apr 1;30(4):558-566. link to original article link to PMC article PubMed
Talazoparib monotherapy
back to top |
Regimen
FDA-recommended dose |
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Litton et al. 2018 (EMBRACA) | 2013-2017 | Phase III (E-RT-switch-ooc) | Physician's choice of: 1. Capecitabine 2. Eribulin 3. Gemcitabine 4. Vinorelbine |
Superior PFS |
Targeted therapy
- Talazoparib (Talzenna) 1 mg PO once per day
Continued indefinitely
References
- EMBRACA: Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018 Aug 23;379(8):753-763. Epub 2018 Aug 15. link to original article contains protocol PubMed
Vinorelbine monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Robson et al. 2017 (OlympiAD) | 2014-2015 | Phase III (C) | Olaparib | Inferior PFS |
Patients had confirmed deleterious or suspected deleterious germline BRCA mutation.
Chemotherapy
- Vinorelbine (Navelbine) 30 mg/m2 IV once per day on days 1 & 8
21-day cycles
References
- OlympiAD: Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. Epub 2017 Jun 4. link to original article contains verified protocol PubMed
- Update: Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Apr 1;30(4):558-566. link to original article link to PMC article PubMed
- EMBRACA: Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018 Aug 23;379(8):753-763. Epub 2018 Aug 15. link to original article contains protocol PubMed
Additional resources
back to top |